Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Medical University of South Carolina
Lyell Immunopharma, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Essen Biotech
Dana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Gilead Sciences
Chinese PLA General Hospital
Chinese PLA General Hospital
Chinese PLA General Hospital
Artiva Biotherapeutics, Inc.
Indapta Therapeutics, INC.
Thomas Jefferson University
Chinese PLA General Hospital
Affiliated Hospital to Academy of Military Medical Sciences
Hoffmann-La Roche
Celgene
University Hospital Heidelberg
Columbia University
Uppsala University
M.D. Anderson Cancer Center
Gilead Sciences
Chinese PLA General Hospital
Indiana University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Chongqing University Cancer Hospital
TCR2 Therapeutics
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Precision BioSciences, Inc.
National Institutes of Health Clinical Center (CC)
Beijing Immunochina Medical Science & Technology Co., Ltd.
GC Cell Corporation
Baylor College of Medicine
M.D. Anderson Cancer Center
Columbia University
Columbia University
Masonic Cancer Center, University of Minnesota
Henan Cancer Hospital